瑞思迈 RMD

Mr. Michael J. Farrell. Current Public Company Directorships: Zimmer Biomet (NYSE: ZBH) - Director (2014-present); Lead Independent Director (2025-present); Member of the Compensation and Management Development Committee; Member of the Quality, Regulatory and Technology Committee; Business Experience: ResMed Inc. (NYSE: RMD) - Chairman of the Board (January 2023-present); Chief Executive Officer and Director (March 2013-present); President of the Americas Region (2011-2013); Senior Vice President of the Global Sleep Apnea Diagnostic and Therapeutic Business (2007-2011); Senior roles in Marketing and Business Development (2000-2007); Other Experience: Chair, Board of Directors, Advanced Medical Technology Association (AdvaMed); Trustee for University of California, San Diego Foundation, Rady Children's Hospital, and Father Joe's Villages' project for the homeless in San Diego, California; Chair, University of California San Diego Rady School of Management Dean's Advisory Council; Honoree, American Australian Association (2025); Honoree, Public Service Star Award from the Singapore National Day Awards (2026); Education and Professional Credentials: Bachelor of Engineering with first-class honors from the University of New South Wales; Master of Science in chemical engineering from the Massachusetts Institute of Technology (MIT); Master of Business Administration from the MIT Sloan School of Management.

Justin Leong has served as our chief product officer since November 2023 and is responsible for leading the company's global product organization, including product strategy and management, hardware and software engineering, AI engineering and data science, commercial transformation, disruptive growth innovation and new business creation, user experience (UX) and customer experience (CX) design, product operations, product marketing, and business development and partnerships. Prior to his current role, Mr. Leong held a series of increasingly senior leadership positions at Resmed since joining the Company in 2013 as Vice President, Global Strategy, including president of Resmed's Asia and Latin American markets, president of Asia Growth Markets, and senior vice president and general manager of greater China. Before joining Resmed, Mr. Leong was a director at London-based private equity firm HgCapital from 2006 to 2012, responsible for acquisitions and portfolio management. From 1999 to 2004, he was a management consultant with Bain & Co. in Sydney, Boston, and New York. Mr. Leong holds a Bachelor of Commerce and a Bachelor of Laws from the University of New South Wales, Sydney, and a Master of Business Administration from the Harvard Business School.

Aaron Bloomer was appointed chief financial officer on May 4, 2026 and is responsible for overseeing the company's global financial strategy, capital allocation, and performance management through disciplined growth, long term value creation, and execution of the company's strategy. From May 2024 to May 2026, Mr. Bloomer served as chief financial officer of Exact Sciences (NASDAQ: EXAS), a global leader in cancer diagnostics. From August 2021 to May 2024, Mr. Bloomer served as the Vice President, Corporate Financial Planning, Reporting, and Analytics for Baxter International Inc. (NYSE: BAX). From June 2008 to August 2021, Mr. Bloomer held a series of increasingly senior roles with 3M Company (NYSE: MMM), including Senior Vice President, Corporate Financial Planning, Reporting and Analytics of 3M, and Vice President and CFO of 3M's Greater China area. Mr. Bloomer holds a Bachelor of Business Administration in Finance from the University of Wisconsin-Eau Claire and a Master of Business Administration from the University of Minnesota.

Michael Mike Rider has served as our global general counsel and secretary since July 2023. Mr. Rider previously served as Resmed's senior vice president, deputy global general counsel, and legal business partner for Resmed's sleep and respiratory care team from July 2019 through June 2023 and as vice president and general counsel-Americas from June 2012 to July 2019. Prior to joining Resmed, Mr. Rider served as senior vice president, general counsel for Callaway Golf (NYSE: CALY), senior attorney for American Airlines (NASDAQ: AAL), and as a litigation associate at Gibson Dunn & Crutcher. Mr. Rider graduated magna cum laude from the University of San Diego School of Law. Mr. Rider earned a Bachelor of Science in Pharmacy from the University of Arizona.

Dr. Peter C. Farrell, A.M.,PhD. Current Public Company Directorships: Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) (2018-present) - Director, former Board Chair, member of the Compensation and Nominating and Corporate Governance Committees; Prior Public Company Directorships: NuVasive, Inc. (NASDAQ: NUVA); Evolus, Inc. (NASDAQ: EOLS) (2019-2023); Business Experience: ResMed Inc. - Chairman Emeritus (January 2023-present); Board Chairman (May 1989-January 2023); Chief Executive Officer (July 1990-December 2007; February 2011-March 2013); Non-officer employee (January 2014-present); Founder and Director (1989-present); Baxter International, Inc. (NYSE: BAX) - Managing Director of the Baxter Center for Medical Research Pty Ltd. (August 1985-June 1989); University of New South Wales - Visiting Professor and former Chair of the UNSW Centre for Innovation and Entrepreneurship (1989-present); Foundation Director of the Graduate School for Biomedical Engineering (January 1978-December 1989); MIT - Member, MIT Dean of Engineering's Advisory Council (2018-present); Member, Visiting Committee of the Harvard-MIT Health Sciences & Technology Program (1998-2018); Other Service: Faculty Advisory Board at UC, San Diego, the Jacobs Engineering School; Board of Trustees of Scripps Research Institute; Executive Council of the Division of Sleep Medicine, Harvard Medical School; Education and Professional Credentials: B.E. in chemical engineering with honors from the University of Sydney; S.M. in chemical engineering from MIT; Ph.D. in chemical engineering and bioengineering from the University of Washington, Seattle; D.Sc. from the University of New South Wales.

Ronald Taylor, Pyxis Corporation, a manufacturer of automated drug dispensers for hospitals- 1987 to 1996 - Founder, Chairman, and chief executive officer until its sale to Cardinal Health, Inc. Hybritech, Inc., a biotechnology company- Responsible for operations and international sales. Allergan plc (NYSE: AGN), a pharmaceutical company- Served in operational and management roles. Enterprise Partners Venture Capital- 1998 to 2001 - General partner. Other Experience- Resmed Foundation-- 2002 to 2005 - Chair of the board. Education and Professional Credentials- Bachelor of Arts in Chemistry from the University of Saskatchewan and Master of Arts in Chemistry from the University of California, Irvine. Prior Public Company Directorships (representative): Allergan (NYSE: AGN) Medicalogic (NASDAQ: MDLI) Red Lion Hotels (NYSE: RLH). On August 13, 2026, Ronald Taylor, a director of Resmed, informed the Board that he will not stand for election at Resmed's 2026 annual meeting of stockholders and intends to retire from the Board, effective at the Annual Meeting, which is expected to be held on November 18, 2026.

Ms. Nicole Mowad-Nassar. Business Experience: AbbVie Inc. (NYSE: ABBV) - Senior Vice President, AbbVie and President, Global Allergan Aesthetics (September 2025-present); Senior Vice President, AbbVie and President, Specialty & U.S. Therapeutics Operations (July 2023-August 2025); VP, Commercial Analytics & Operations, AbbVie Patient Services (January 2020-July 2023); VP, Commercial Analytics and Operations and Global Commercial Integration Lead, Allergan Acquisition (January 2018-January 2020); Takeda Pharmaceuticals USA, Inc. (NYSE: TAK) - Progressive leadership roles including VP and Head of U.S. Business Operations and External Partnerships and VP, U.S. Marketing (2009-2017); Abbott Laboratories (NYSE: ABT) - Progressive leadership roles in the Hospital Products Division and the Pharmaceutical Products Division (2000-2009); Other Experience: Serves on AbbVie's Environmental, Social & Governance Steering Council and the Executive Crisis Management Team; Past board member of Cristo Rey St. Martin College Prep and Lake Forest High School; Education and Professional Credentials: Bachelor of Arts in Economics from Bucknell University; Master of Business Administration, Kellogg School of Business, Northwestern University.

Mr. Christopher J. DelOrefice. Business Experience: Ulta Beauty (NASDAQ: ULTA) - Chief Financial Officer (December 2025-present); Becton, Dickinson and Company (BD) (NYSE: BDX) - Executive Vice President and Chief Financial Officer (September 2021-December 2025); Johnson & Johnson (NYSE: JNJ) - Vice President, Investor Relations (August 2018-September 2021); Variety of senior finance leadership roles, including CFO of both the Consumer and Medical Devices segments for North America (1999-2018); Education and Professional Credentials: Bachelor of Science in Accounting from Villanova University; M.B.A. from Villanova University; Certified Public Accountant (inactive).

Ms. Karen Drexler. Current Public Company Directorships: Outset Medical (NASDAQ: OM) - Director (2021-present); Chair of Nominating and Corporate Governance Committee and member of the Compensation Committee; EBR Systems, Inc. (ASX: EBR) - Director (2021-present); Chair of the Nomination and Remuneration Committee, member of the Audit and Risk Committee; Prior Public Company Directorships: Tivic Health (NASDAQ: TIVC) (2019-2024); Business Experience: Sandstone Diagnostics, Inc. - Board Member and CEO (2016-2020); Amira Medical Inc. - Founder, President and CEO until sold to Roche Holding AG; Other Experience: Active mentor and advisor with Astia and a lead mentor with StartX; Serves on the Women's Health Council for Springboard; Elected to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows; Education and Professional Credentials: Graduated magna cum laude with a B.S.E. in chemical engineering from Princeton University; M.B.A. with honors from Stanford University Graduate School of Business.

Carol Burt, Current Public Company Directorships: IQVIA Holdings Inc. (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry (2019-present). Business Experience- Burt-Hilliard Investments, a private investment firm- 2008 to present - Principal. Consonance Capital Partners, a New York-based private equity firm focused on investments in the healthcare industry- 2013 to present - Senior Advisor and a member of the Operating Council. WellPoint, Inc. (now Elevance Health, Inc., NYSE: ELV)- Senior Vice President of Corporate Finance and Development. American Medical Response- Senior Vice President and Treasurer. Chase Securities, Inc. (now JP Morgan Chase & Co, NYSE: JPM)- Founder, Managing Director and Head of the Health Care Banking Group. Other Experience- Member of Women Corporate Directors, and the International Women's Forum. Education and Professional Credentials- Graduated magna cum laude from the University of Houston, earning a Bachelor of Business Administration. Prior Public Company Directorships: Envision Healthcare Corp. (NYSE:EVHC); Vanguard Health Systems Inc. (NYSE: VHS) and WellCare Health Plans, Inc. (NYSE: WCG). The Board approved the appointment of Carol Burt as lead director, effective November 15, 2026.

Ms. Harjit Gill. Business Experience: Asia Pacific Medical Technology Association (APACMed) - Chief Executive Officer (February 2019-December 2025); Alticor, Inc. - Director and member of the Audit and Cybersecurity Committees (January 2022-present); MAS Holdings - Director and member of the Innovation Board of Directors (2019-December 2025); Royal Philips (NYSE: PHG) - Progressive leadership roles, including Executive Vice President and CEO for Philips ASEAN & Pacific (1990-2015); Other Experience: Member of the academic committee of the China-ASEAN Science and Technology Cooperation Center for Public Health at Peking University (China); Education and Professional Credentials: Bachelor of Arts (honors) in combined studies from the University of Manchester.

Mr. Jan De Witte. Business Experience: GHO Capital Partners LLP - Operating Partner (February 2025-present); FotoFinder Group GmbH - Chairman (September 2025-present); Integra Life Sciences (NASDAQ: IART) - President, Chief Executive Officer and Director (October 2021-January 2025); Barco (EBR: BAR) - CEO and Director (2016-2021); General Electric Company (NYSE: GE) - Progressive leadership roles, including President and CEO of GE Global Healthcare IT (1999-2016); Director at Advanced Medical Technology Association (AdvaMed); Senior Consultant at McKinsey & Co. and Operations roles at Procter & Gamble in Europe; Current Public Company Directorships: Elekta (B.ST: EKTA) - Director (2025-present); Member of the Strategy and Innovation Committee; Prior Public Company Directorships: BARCO (EBR: BAR); Integra Life Sciences (NASDAQ: IART) (2021-2025); Education and Professional Credentials: Bachelor's degree in electromechanical engineering from KU Leuven in Belgium; Master of Science degree in electromechanical engineering with Greatest Distinction from KU Leuven in Belgium; M.B.A. from Harvard Business School.

Dr. Desney Tan, PhD. Business Experience: SeaX Ventures - Venture Partner (August 2026-present); Microsoft (NASDAQ: MSFT) - Corporate Vice President and Managing Director of Microsoft Research (2023-January 2026); Vice President and Managing Director of Microsoft Health Futures (2021-2023); Managing Director of Microsoft Healthcare (2015-2021); Various roles leading research and development (2004-2015); University of Washington Seattle - Affiliate Professor of Computer Science and Engineering (2007-present); Other Experience: Serves on the Washington Research Foundation's Board of Directors; Senior Advisor and Chief Technologist to IntuitiveX; Advisor to Proprio and NewDays; Education and Professional Credentials: Bachelor of Science (summa cum laude) in computer engineering from the University of Notre Dame; Doctor of Philosophy in computer science from Carnegie Mellon University.

Dr. John Hernandez, PhD. Prior Public Company Directorships: Carmat, SA (ALCAR.PA) (2021-2024); Business Experience: Google, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL) - Head of Clinical Research, Health Economics and Outcomes Research (2018-present); Head of Health Economics and Outcomes Research, Real-World Evidence and Biometrics (2016-2018); Abbott Laboratories (NYSE: ABT) - Vice President of Global Health Economics and Outcomes Research (2010-2016); Boston Scientific Corporation (NYSE: BSX) - Vice President of Clinical Research and Health Economics (2001-2010); Other Experience: Widely published in scientific journals and lectures on various topics including digital health strategy, health policy, health economics, healthcare technology assessment, value-based payments and real-world evidence strategies; Education and Professional Credentials: Bachelor of Arts from the University of North Carolina at Chapel Hill; Master's degree in health policy analysis from the RAND School of Public Policy; Doctorate of Philosophy in health policy from the RAND School of Public Policy.